(6-oxabicyclo[3.1.0]hexan-3-yl)methanol | 36368-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (6-oxabicyclo[3.1.0]hexan-3-yl)methanol
• 英文别名: 1,2-Epoxy-4-hydroxymethylcyclopentane；6-oxabicyclo[3.1.0]hexan-3-ylmethanol
• CAS: 36368-44-2
• 化学式: C₆H₁₀O₂
• 分子量: 114.144
• InChiKey: ZWMXHPOWONDHGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (6-oxabicyclo[3.1.0]hexan-3-yl)methanol 在 氨 、 碳酸氢钠 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  [EN] TARGETED COMPOSITIONS
  [FR] COMPOSITIONS CIBLÉES

  摘要：

  公开号：

  WO2018191278A3
• 作为产物：
  描述：

  3-环戊烯-1-甲酸甲酯 在 lithium aluminium tetrahydride 、 间氯过氧苯甲酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 (6-oxabicyclo[3.1.0]hexan-3-yl)methanol
  参考文献：
  名称：

  [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS
  [FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS

  摘要：

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。

  公开号：

  WO2017177326A1

文献信息

• [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS<br/>[FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2017177326A1

  公开（公告）日：2017-10-19

  The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。
• Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
  申请人：——

  公开号：US20030087873A1

  公开（公告）日：2003-05-08

  The disclosed invention is a composition for and a method of treating a Flaviviridae (including BVDV and HCV), Orthomyxoviridae (including Influenza A and B) or Paramyxoviridae (including RSV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans, using a nucleoside of general formula (I)-(XXIII) or its pharmaceutically acceptable salt or prodrug. This invention also provides an effective process to quantify the viral load, and in particular BVDV, HCV or West Nile Virus load, in a host, using real-time polymerase chain reaction (“RT-PCR”). Additionally, the invention discloses probe molecules that can fluoresce proportionally to the amount of virus present in a sample.

  该公开的发明涉及一种用于治疗Flaviviridae（包括BVDV和HCV）、Orthomyxoviridae（包括甲型和乙型流感）或Paramyxoviridae（包括RSV）感染或与异常细胞增殖有关的病况的组合物和方法，适用于宿主，包括动物，尤其是人类，使用通用式（I）-（XXIII）的核苷或其药学上可接受的盐或前药。该发明还提供了一种有效的过程，用于量化病毒载量，特别是BVDV、HCV或西尼罗河病毒载量，使用实时聚合酶链反应（RT-PCR）。此外，该发明揭示了可以与样本中存在的病毒数量成比例发光的探针分子。
• 2'-fluoronucleosides
  申请人：——

  公开号：US20020198171A1

  公开（公告）日：2002-12-26

  A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: 1 wherein Base is a purine or pyrimidine base; R 1 is OH, H, OR 3 , N 3 , CN, halogen, including F, or CF 3 , lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base; R 2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R 2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and R 3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

  本发明揭示了一类2'-氟核苷类化合物，其可用于治疗乙型肝炎感染、丙型肝炎感染、艾滋病毒和异常细胞增殖，包括肿瘤和癌症。该化合物具有以下通式： 其中，基团表示嘌呤或嘧啶碱基；R1为OH、H、OR3、N3、CN、卤素（包括F）或CF3、低烷基、氨基、低烷基氨基、二（低）烷基氨基或烷氧基，基团表示嘌呤或嘧啶碱基；R2为H、磷酸酯（包括一磷酸盐、二磷酸盐、三磷酸盐或稳定的磷酸酯前药）、酰基或其他在体内可提供R2为H或磷酸酯的药学上可接受的离去基团；磺酸酯包括烷基或芳基烷基磺酰基，包括甲烷磺酰基、苄基，其中苯基基团可选择地被一个或多个如上所述的取代基所取代，脂质、氨基酸、肽或胆固醇；以及R3为酰基、烷基、磷酸酯或其他在体内可裂解为母体化合物的药学上可接受的离去基团，或其药学上可接受的盐。
• PHOTOPOLYMERIZABLE VINYL ETHER BASED MONOMERIC FORMULATIONS AND POLYMERIZABLE COMPOSITIONS WHICH MAY INCLUDE CERTAIN NOVEL SPIROORTHOCARBONATES
  申请人：——

  公开号：US20020013380A1

  公开（公告）日：2002-01-31

  Photopolymerizable compositions are provided which are the reaction products of a vinyl ether, a photoinitiator system comprising an iodonium salt, a visible light sensitizer, and an electron donor compound. These monomeric/oligomeric compositions may also include epoxides, polyols, spiroorthocarbonates. One embodiment of the present invention is a polymerizable composition comprised of a vinyl ether, a spiroorthocarbonate, and a photoinitiator system. Another embodiment of the present invention is a polymerizable composition comprised of a vinyl ether, an epoxide, a polyol, and a photoinitiator system. Still another embodiment of the present invention is a polymerizable composition comprised of a vinyl ether, an epoxide, a polyol, a spiroorthocarbonate, and a photoinitiator system. Still further, another embodiment of the present invention is certain novel spiroorthocarbonate compounds. Each of these novel spiroorthocarbonate compounds include at least one epoxy group as a substituent.

  提供了光聚合组合物，其为乙烯醚、包括碘化物盐、可见光敏化剂和电子供体化合物的光引发剂体系的反应产物。这些单体/低聚物组合物还可以包括环氧化合物、多元醇、螺环正交碳酸酯。本发明的一种实施例是由乙烯醚、螺环正交碳酸酯和光引发剂体系组成的聚合物组合物。本发明的另一种实施例是由乙烯醚、环氧化合物、多元醇和光引发剂体系组成的聚合物组合物。本发明的另一种实施例是由乙烯醚、环氧化合物、多元醇、螺环正交碳酸酯和光引发剂体系组成的聚合物组合物。此外，本发明的另一种实施例是某些新型螺环正交碳酸酯化合物。这些新型螺环正交碳酸酯化合物中，每个化合物都包括至少一个环氧基团作为取代基。
• 2'-Fluoronucleosides
  申请人：——

  公开号：US20040254141A1

  公开（公告）日：2004-12-16

  A class of 2′-fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: 1 wherein Base is a purine or pyrimidine base; R 1 is OH, H, OR 3 , N 3 , CN, halogen, including F, or CF 3 , lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy, and base refers to a purine or pyrimidine base; R 2 is H, phosphate, including monophosphate, diphosphate, triphosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of providing a compound wherein R 2 is H or phosphate; sulfonate ester including alkyl or arylalkyl sulfonyl including methanesulfonyl, benzyl, wherein the phenyl group is optionally substituted with one or more substituents as described in the definition of aryl given above, a lipid, an amino acid, peptide, or cholesterol; and R 3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group which when administered in vivo, is capable of being cleaved to the parent compound, or a pharmaceutically acceptable salt thereof.

  本发明涉及一类2'-氟核苷化合物，其在治疗乙型肝炎感染、丙型肝炎感染、HIV和异常细胞增殖，包括肿瘤和癌症方面有用。该化合物具有以下通用式：1其中Base是嘌呤或嘧啶碱基；R1是OH、H、OR3、N3、CN、卤素，包括F或CF3、低烷基、氨基、低烷基氨基、二（低）烷基氨基或烷氧基，且base是指嘌呤或嘧啶碱基；R2是H、磷酸，包括一磷酸盐、二磷酸盐、三磷酸盐或稳定的磷酸盐前药；酰基或其他在体内可以提供R2为H或磷酸的药学上可接受的离去基；磺酸酯，包括烷基或芳基烷基磺酰，包括甲烷磺酰、苯甲基，其中苯基可以选择性地用上述芳基定义中描述的一个或多个取代基置换；脂质、氨基酸、肽或胆固醇；以及R3是酰基、烷基、磷酸盐或其他在体内可以裂解为母化合物的药学上可接受的离去基，或其药学上可接受的盐。